Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.76 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937913 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL5953353 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL5937944 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL10015739 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL16489726 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL75905 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL5492449 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL3629423 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL20663990 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 | |
| SCHEMBL5494929 | 0.89 | NFE2L2 (0.56) | NFE2L2APPPTGS1ALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304095-B2 | Organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20080272693-A1 | Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080272693-A1 | Organic Electroluminescent Devices | EML4, MT-ND4L, EPCAM | NFE2L2 423/4885APP 2549/4885ACHE 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.